Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETTX Entasis Therapeutics	$2.19	$2.19	$1.40 ▼ $3.88	$104.80M	1.33	239,104 shs	800 shs
PGEN Precigen	$1.42 -0.7%	$1.44	$0.65 ▼ $2.17	$419.16M	1.85	1.39 million shs	5.16 million shs
STOK Stoke Therapeutics	$11.63 -1.8%	$10.22	$5.35 ▼ $16.15	$635.00M	1.09	673,529 shs	1.37 million shs
UPB Upstream Bio	$10.93 -0.1%	$9.81	$5.14 ▼ $29.46	$587.93M	N/A	352,831 shs	3.04 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETTX Entasis Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PGEN Precigen	0.00%	-2.07%	+7.58%	-4.70%	-10.13%
STOK Stoke Therapeutics	0.00%	+0.43%	+21.02%	+74.89%	-13.92%
UPB Upstream Bio	0.00%	+0.46%	+19.45%	+78.59%	+1,092,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	3.9743 of 5 stars	3.5	1.0	0.0	4.7	2.2	1.7	0.6
STOK Stoke Therapeutics	3.9845 of 5 stars	3.6	0.0	0.0	4.8	2.4	0.8	1.3
UPB Upstream Bio	1.8271 of 5 stars	3.5	0.0	0.0	0.0	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETTX Entasis Therapeutics	0.00	N/A	N/A	N/A
PGEN Precigen	3.00	Buy	$6.00	322.54% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	99.48% Upside
UPB Upstream Bio	3.00	Buy	$56.50	416.93% Upside

Current Analyst Ratings Breakdown

Latest ETTX, PGEN, STOK, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETTX Entasis Therapeutics	$7M	14.97	N/A	N/A	$0.66 per share	3.32
PGEN Precigen	$3.92M	106.93	N/A	N/A	$0.13 per share	10.92
STOK Stoke Therapeutics	$36.56M	17.37	N/A	N/A	$4.32 per share	2.69
UPB Upstream Bio	$2.37M	248.07	N/A	N/A	$8.77 per share	1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETTX Entasis Therapeutics	-$47.14M	-$1.12	N/A	N/A	N/A	N/A	-145.48%	-103.75%	N/A
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.72	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest ETTX, PGEN, STOK, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETTX Entasis Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETTX Entasis Therapeutics	N/A	1.65	1.65
PGEN Precigen	N/A	3.53	3.53
STOK Stoke Therapeutics	N/A	8.41	8.41
UPB Upstream Bio	N/A	47.43	47.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETTX Entasis Therapeutics	6.91%
PGEN Precigen	33.51%
STOK Stoke Therapeutics	N/A
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ETTX Entasis Therapeutics	6.50%
PGEN Precigen	47.10%
STOK Stoke Therapeutics	9.50%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETTX Entasis Therapeutics	51	47.85 million	44.74 million	Not Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable
UPB Upstream Bio	38	53.79 million	46.50 million	N/A

ETTX, PGEN, STOK, and UPB Headlines

Recent News About These Companies

UPB Upstream Bio, Inc. - Seeking Alpha

June 28 at 2:00 AM | seekingalpha.com

Upstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?

June 20, 2025 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?

June 18, 2025 | marketbeat.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What Happened

June 16, 2025 | marketbeat.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 15, 2025 | msn.com

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress

June 15, 2025 | quiverquant.comQ

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

June 15, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen

June 6, 2025 | marketbeat.com

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025

June 5, 2025 | quiverquant.comQ

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

June 5, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?

June 4, 2025 | marketbeat.com

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What Happened

June 3, 2025 | marketbeat.com

1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLP

June 1, 2025 | marketbeat.com

Upstream Bio names new chief technology officer

May 21, 2025 | investing.com

Upstream Bio Appoints Stacy Price As CTO

May 21, 2025 | nasdaq.com

Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations

May 21, 2025 | nasdaq.com

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025 | globenewswire.com

Upstream Bio Advances Verekitug in Clinical Trials

May 7, 2025 | tipranks.com

Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position

May 6, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETTX, PGEN, STOK, and UPB Company Descriptions

Entasis Therapeutics NASDAQ:ETTX

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Precigen NASDAQ:PGEN

$1.42 -0.01 (-0.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.32 -0.10 (-7.04%)

As of 04:00 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stoke Therapeutics NASDAQ:STOK

$11.63 -0.21 (-1.77%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.17 -0.46 (-3.96%)

As of 04:02 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Upstream Bio NASDAQ:UPB

$10.93 -0.01 (-0.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.00 +0.06 (+0.59%)

As of 04:00 AM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time